303 related articles for article (PubMed ID: 15254775)
1. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
2. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
Luan YZ; Li L; Li DR; Zhang W; Tang BJ
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
5. [The expression of multiple drug resistance associated genes in ovarian cancer].
Cheng G; Zhu H; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):87-90. PubMed ID: 11809106
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Busschots S; O'Toole S; O'Leary JJ; Stordal B
Exp Cell Res; 2015 Aug; 336(1):1-14. PubMed ID: 25499884
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
8. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Masanek U; Stammler G; Volm M
Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
10. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
12. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines.
Wang J; Zhang J; Zhang L; Zhao L; Fan S; Yang Z; Gao F; Kong Y; Xiao GG; Wang Q
Oncol Rep; 2011 Nov; 26(5):1081-9. PubMed ID: 21805041
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
14. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis].
Cao DY; Shen K; Yang JX; Guan J
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1738-41. PubMed ID: 17919376
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
16. [Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin].
Xu RH; Yuan ZY; Guan ZZ; Li S
Ai Zheng; 2005 Aug; 24(8):975-9. PubMed ID: 16086876
[TBL] [Abstract][Full Text] [Related]
17. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
18. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
19. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
